268 related articles for article (PubMed ID: 31734720)
21. Fundus autofluorescence findings in central serous chorioretinopathy using two different confocal scanning laser ophthalmoscopes: correlation with functional and structural status.
Shin JY; Choi HJ; Lee J; Choi M; Chung B; Byeon SH
Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1537-1544. PubMed ID: 26690973
[TBL] [Abstract][Full Text] [Related]
22. Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids.
Haimovici R; Gragoudas ES; Duker JS; Sjaarda RN; Eliott D
Ophthalmology; 1997 Oct; 104(10):1653-60. PubMed ID: 9331207
[TBL] [Abstract][Full Text] [Related]
23. Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients.
Ersoz MG; Arf S; Hocaoglu M; Sayman Muslubas I; Karacorlu M
Br J Ophthalmol; 2019 Jun; 103(6):725-729. PubMed ID: 30002072
[TBL] [Abstract][Full Text] [Related]
24. Recurrent Central Serous Chorioretinopathy with Dexamethasone Eye Drop used Nasally for Rhinitis.
Prakash G; Shephali J; Tirupati N; Ji PD
Middle East Afr J Ophthalmol; 2013; 20(4):363-5. PubMed ID: 24339692
[TBL] [Abstract][Full Text] [Related]
25. Retinal sensitivity after selective retina therapy (SRT) on patients with central serous chorioretinopathy.
Yasui A; Yamamoto M; Hirayama K; Shiraki K; Theisen-Kunde D; Brinkmann R; Miura Y; Kohno T
Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):243-254. PubMed ID: 27497611
[TBL] [Abstract][Full Text] [Related]
26. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy.
Ma J; Meng N; Xu X; Zhou F; Qu Y
Acta Ophthalmol; 2014 Dec; 92(8):e594-601. PubMed ID: 25042260
[TBL] [Abstract][Full Text] [Related]
27. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
[TBL] [Abstract][Full Text] [Related]
28. Vascular and structural alterations of the choroid evaluated by optical coherence tomography angiography and optical coherence tomography after half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Demirel S; Özcan G; Yanık Ö; Batıoğlu F; Özmert E
Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):905-912. PubMed ID: 30617579
[TBL] [Abstract][Full Text] [Related]
29. Central serous chorioretinopathy in elderly subjects: angiographic and tomographic characteristics.
Bae K; Nam SW; Kang SW; Kim ES; Yu SY; Kim KT; Kim SJ
Graefes Arch Clin Exp Ophthalmol; 2019 Feb; 257(2):279-288. PubMed ID: 30564905
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of choroidal hyperreflective dots in acute and chronic central serous chorioretinopathy.
Hanumunthadu D; Matet A; Rasheed MA; Goud A; Vuppurabina KK; Chhablani J
Indian J Ophthalmol; 2019 Nov; 67(11):1850-1854. PubMed ID: 31638047
[TBL] [Abstract][Full Text] [Related]
31. Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis.
Ji S; Wei Y; Chen J; Tang S
Int J Clin Pharm; 2017 Jun; 39(3):514-521. PubMed ID: 28386700
[TBL] [Abstract][Full Text] [Related]
32. COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY.
Lee JH; Lee SC; Kim H; Lee CS
Retina; 2019 Jan; 39(1):127-133. PubMed ID: 29095358
[TBL] [Abstract][Full Text] [Related]
33. Morphological and Functional Changes Immediately After Half-Time Photodynamic Therapy in Patients With Central Serous Chorioretinopathy.
Muslubas IS; Ersoz MG; Hocaoglu M; Arf S; Karacorlu M
Ophthalmic Surg Lasers Imaging Retina; 2018 Dec; 49(12):932-940. PubMed ID: 30566700
[TBL] [Abstract][Full Text] [Related]
34. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
van Dijk EHC; Dijkman G; Boon CJF
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
[TBL] [Abstract][Full Text] [Related]
36. [Bilateral central serous chorioretinopathy post-COVID-19].
Mahjoub A; Dlensi A; Romdhane A; Ben Abdesslem N; Mahjoub A; Bachraoui C; Mahjoub H; Ghorbel M; Knani L; Krifa F
J Fr Ophtalmol; 2021 Dec; 44(10):1484-1490. PubMed ID: 34756744
[TBL] [Abstract][Full Text] [Related]
37. Masqueraders of central serous chorioretinopathy.
Sahoo NK; Singh SR; Rajendran A; Shukla D; Chhablani J
Surv Ophthalmol; 2019; 64(1):30-44. PubMed ID: 30243734
[TBL] [Abstract][Full Text] [Related]
38. Cytokine levels of the aqueous humour in central serous chorioretinopathy.
Jung SH; Kim KA; Sohn SW; Yang SJ
Clin Exp Optom; 2014 May; 97(3):264-9. PubMed ID: 24417755
[TBL] [Abstract][Full Text] [Related]
39. Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy.
Koytak A; Erol K; Coskun E; Asik N; Öztürk H; Özertürk Y
Retina; 2010; 30(10):1698-703. PubMed ID: 20539254
[TBL] [Abstract][Full Text] [Related]
40. RISK FACTORS FOR RECURRENCES OF CENTRAL SEROUS CHORIORETINOPATHY.
Matet A; Daruich A; Zola M; Behar-Cohen F
Retina; 2018 Jul; 38(7):1403-1414. PubMed ID: 28570485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
